Mitumomab: Difference between revisions
Content deleted Content added
Anypodetos (talk | contribs) Sourced, rephrased and slightly expanded |
Anypodetos (talk | contribs) Added code no. and additional source |
||
| Line 27: | Line 27: | ||
}} |
}} |
||
'''Mitumomab''' is a [[mouse]] [[monoclonal antibody]] investigated for the treatment of [[small cell lung carcinoma]] in combination with [[Bacillus Calmette-Guérin|BCG]] vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the [[immune system]]. {{as of|September 2009}}, the drug is undergoing Phase III [[clinical trials]].<ref>[http://clinicaltrials.gov/ct2/show/NCT00006352 ClinicalTrials.gov]</ref> |
'''Mitumomab''' ('''BEC-2''') is a [[mouse]] [[monoclonal antibody]] investigated for the treatment of [[small cell lung carcinoma]] in combination with [[Bacillus Calmette-Guérin|BCG]] vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the [[immune system]]. {{as of|September 2009}}, the drug is undergoing Phase III [[clinical trials]].<ref>[http://clinicaltrials.gov/ct2/show/NCT00006352 ClinicalTrials.gov]</ref><ref>[http://www.pcpoh.bham.ac.uk/publichealth/horizon/outputs/documents/2003/BEC2.pdf BEC-2 for small cell lung cancer]</ref> |
||
==See also== |
==See also== |
||
*[[Anti-ganglioside antibodies]] |
*[[Anti-ganglioside antibodies]] |
||
Revision as of 20:20, 24 September 2009
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Mouse |
| Target | CD3 ganglioside |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
Mitumomab (BEC-2) is a mouse monoclonal antibody investigated for the treatment of small cell lung carcinoma in combination with BCG vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the immune system. As of September 2009[update], the drug is undergoing Phase III clinical trials.[1][2]
See also
References
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |